Competition Council approves take over of part of Astra Zeneca’s assets by Recordati

The Competition Council approves the take over of a part of Astra Zeneca’s assets by Recordati in order to sell pharma products Betaloc and Betaloc ZOK in Romania.

„The objective of the economic concentration operation is represented by assets and exclusive rights on the sale of three pharma products for cardio-vascular diseases, Betaloc, Betaloc ZOK and Logimax in certain European countries and Israel. Competition council evaluated the economic concentration operator from the point of view of their compatibility with a normal competitive environment, respectively the possible non-competitive effects, according to the regulation on the economic concentrations. The analysis showed that the operation doesn’t bring obstacles on the national competition,” says the source.

Recordati S.p.A is a pharma company, active in research, factory and sale of pharma products and active pharma substances.